Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...
Fintel reports that on January 10, 2025, Cantor Fitzgerald initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a ...
We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...
Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share estimates for Maplebear in a research note issued on Tuesday, January 7th. Cantor Fitzgerald analyst D. Mathivanan now ...
Analysts at Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for Meta Platforms in a research note ...
Cantor Fitzgerald initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and no price target The company’s emerging ...
In a recent blog post, OpenAI CEO Sam Altman said that as OpenAI continues to advance it has moved beyond research to product ...
In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Avita Medical (RCEL – Research Report), with a ...
Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it closed its initial public offering ...
Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it closed its initial public offering of 20,000,000 Class A ordinary shares at $10.00 per share. The shares began ...
Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it priced its initial public offering ...